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1148Available online 8 June 2021Background: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab
govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked with the
topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment of physician’s choice (TPC) in previously
treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from the
ASCENT trial evaluates the association between tumor Trop-2 expression and germline BRCA1/2 mutation status
with clinical outcomes.
Patients and methods: Patients with mTNBC refractory to or progressing after two or more prior chemotherapies, with
one or more in the metastatic setting, were randomized to receive SG (10 mg/kg intravenously days 1 and 8, every 21
days) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Biopsy
or surgical specimens were collected at study entry to determine Trop-2 expression level using a validated
immunohistochemistry assay and histochemical scoring. Germline BRCA1/2 mutation status was collected at baseline.
Results: Of 468 assessable patients, 290 had Trop-2 expression data [64% (n ¼ 151 SG) versus 60% (n ¼ 139 TPC)] and
292 had known BRCA1/2 mutation status [63% (n ¼ 149 SG) versus 61% (n ¼ 143 TPC)]. Median progression-free
survival in SG- versus TPC-treated patients was 6.9, 5.6, and 2.7 months versus 2.5, 2.2, and 1.6 months for high,
medium, and low Trop-2 expression, respectively. Median overall survival (14.2, 14.9, and 9.3 months versus 6.9,
6.9, and 7.6 months) and objective response rates (44%, 38%, and 22% versus 1%, 11%, and 6%) were numerically
higher with SG versus TPC in patients with high, medium, and low Trop-2 expression, respectively. Efficacy
outcomes were numerically higher with SG versus TPC in patients with and without germline BRCA1/2 mutations.
Conclusions: SG benefits patients with previously treated mTNBC expressing high/medium Trop-2 compared with
standard-of-care chemotherapy and regardless of germline BRCA1/2 mutation status. The small number of patients
with low Trop-2 expression precludes definitive conclusions on the benefit of SG in this subgroup.
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Precision medicine has gained momentum in recent years,
with increasing attention given to the identification of key
biomarkers that predict response to treatment. Triple-
negative breast cancer (TNBC) is a heterogeneous disease
with distinct molecular subtypes, resulting in unique drug
sensitivities.1,2 A potential biomarker for response in TNBC
is trophoblast cell-surface antigen 2 (Trop-2), a trans-
membrane glycoprotein calcium signal transducer
expressed in human epithelial cells.3 Increased expression
of Trop-2 is associated with tumor growth in a variety of
solid epithelial tumors, including TNBC and other breast
cancer subtypes.3-5 Elevated levels of membrane Trop-2 are
associated with poor prognosis and increased tumor growth
in breast cancer, including decreased survival.3,5
Sacituzumab govitecan (SG) is a novel, Trop-2-directed
antibodyedrug conjugate comprising a humanized anti-
Trop-2 IgG1 kappa antibody coupled to an SN-38
payload, the active metabolite of the topoisomerase 1
inhibitor irinotecan, via a proprietary, hydrolysable linker.
SG is distinct from other antibodyedrug conjugates due
to its high antibody specificity for Trop-2, a high ratio of
drug to antibody (7.6: 1),6 and delivery of SN-38 in its
most active, nonglucuronidated form.7 Following SG
administration, the anti-Trop-2 monoclonal antibody
binds to Trop-2 expressed on the tumor cell surface,
allowing internalization and targeted delivery of SN-38 to
tumor cells.6,8-10 Its proprietary linker also allows SN-38
to be liberated in the tumor microenvironment,
enabling antitumor effects (bystander effect) without
prerequisite internalization and enzymatic cleavage of
SN-38 from the anti-Trop-2 antibody.6,8,11
As BRCA1 or BRCA2 (BRCA1/2) confer a deficiency in
homologous recombination repair of double-stranded DNA
breaks, there is interest in BRCA1/2 as a potential biomarker
of response for therapy regimens that target DNA damage,
particularly for TNBC.12 Approximately 15% of patients with
TNBC have germline BRCA mutations, a higher prevalence
compared with other breast cancer subtypes.13-15 Topo-
isomerase I inhibitors like SN-38, the payload in SG, have
been shown to increase double-stranded DNA breaks,
regardless of BRCA mutation status.14 SG has demonstrated
inhibition of tumor growth in translational models of BRCA-
mutated TNBC and may confer synthetic lethality to TNBC
tumors.14
A phase I/II single-arm basket study (NCT01631552) was
conducted of SG in patients with metastatic, epithelial
cancers. In the cohort of 108 patients with heavily pre-
treated metastatic TNBC (mTNBC), an objective response
rate (ORR) of 33%, median progression-free survival (PFS)
of 5.5 months, and median overall survival (OS) of 13.0
months were observed.16 In this cohort of patients with
mTNBC, 88% of 48 primary or mTNBC tumors had mod-
erate to strong Trop-2 staining, with the majority
expressing Trop-2 in >50% of tumor cells. All responders
had moderate to strong Trop-2 staining, demonstrating theVolume 32 - Issue 9 - 2021potential for greater benefit of SG in tumors with relatively
high Trop-2 expression;17 however, the number of samples
with low or no Trop-2 staining were limited (n ¼ 6),
highlighting the need for further evaluation of Trop-2 in a
larger dataset. The safety and efficacy results from this trial
led to an accelerated approval by the United States Food
and Drug Administration (FDA), with full approval received
based on the results of the phase III ASCENT trial
(NCT02574455).
The randomized phase III ASCENT trial of SG versus
single-agent chemotherapy treatment of physician’s choice
(TPC; eribulin, vinorelbine, gemcitabine, or capecitabine) in
468 patients with chemotherapy-pretreated mTNBC
confirmed the initial findings from the phase I/II study.
Treatment with SG was associated with a significant survival
benefit compared with TPC with a median PFS of 5.6 versus
1.7 months {hazard ratio (HR) 0.41 [95% confidence interval
(CI) 0.32-0.52]; P < 0.001} and a median OS of 12.1 versus
6.7 months [HR, 0.48 (95% CI 0.38-0.59); P < 0.001], along
with a tolerable safety profile. Here, we present a pre-
specified biomarker assessment of the potential association
between tumor membrane Trop-2 expression or germline
BRCA1/2 mutation status on efficacy of SG versus TPC in the
phase III ASCENT study.METHODS
Study design
The study design for ASCENT (NCT02574455) has been
described previously.18 Briefly, ASCENT was an interna-
tional, multicenter, randomized, phase III study
comparing the efficacy and safety of SG versus TPC in
patients in the second-line or greater mTNBC setting.
Patients were stratified at randomization by the number
of prior chemotherapy regimens for advanced disease
(2-3 versus >3), presence of known brain metastases at
baseline (yes versus no), and geography (North America
versus rest of world).
The primary endpoint was PFS (by blinded independent
central review) in patients without known baseline brain
metastases (measured by computed tomography or mag-
netic resonance imaging per RECIST version 1.1).19 Sec-
ondary endpoints included investigator-assessed PFS for the
full population, including all randomized patients with and
without brain metastases, OS, ORR, duration of response,
time to response, and safety. Exploratory endpoints
included biomarker assessment.
The ASCENT trial was conducted and approved by each
investigational site institutional review board/ethics com-
mittee before initiation, and in accordance with the
Declaration of Helsinki, International Council for Harmo-
nisation Guidelines for Good Clinical Practice, FDA Code of
Federal Regulations, national and local drug and data pro-
tection laws, and other applicable regulatory requirements.
All patients provided written informed consent before
enrollment.https://doi.org/10.1016/j.annonc.2021.06.002 1149
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Patients had mTNBC that had progressed following two or
more prior standard chemotherapy regimens (no upper
limit) for unresectable, locally advanced, or metastatic dis-
ease, and included a taxane (any setting). Per protocol,
patients were also eligible after only one prior regimen in
the metastatic setting if their disease recurred within 12
months of completing (neo)adjuvant therapy. Eligible
patients had TNBC according to standard American Society
of Clinical Oncology/College of American Pathologists
criteria.20 Patients with stable brain metastases for at least
4 weeks before treatment were eligible, but were excluded
from evaluation of the primary endpoint and this explor-
atory analysis.
Sample collection and assay procedure
Primary or metastatic archival biopsy or surgical specimens
were requested at study entry to determine tumor Trop-2
expression; however, known Trop-2 expression was not
required to determine patient eligibility. Trop-2 expression
was determined by using a validated immunohistochemistry
(IHC) assay (OptiVIEW DAB detection kit; Roche Diagnostics,
Indianapolis, IN) as specified according to manufacturer
instructions, including quality control methods and by using
Trop-2 mouse monoclonal antibody (ENZ ABS380-0100;
ENZO Life Sciences, Farmingdale, NY). IHC was carried out
centrally (Laboratory Corporation of America, Research
Triangle Park, NC), and interpretation of Trop-2 staining was
carried out by a qualified pathologist.
Tumor cell membrane Trop-2 expression was categorized
based on a histochemical score (H-score), a numerical value
represented by a weighted summation of percent staining
which accounts for both the staining intensity and the
percentage of cells at that intensity. H-scores were calcu-
lated using the following formula: H-score ¼ (3  % cells







Treatment not received (n = 7)
Discontinuations (n = 213)
• n = 199 Progressive disease
• n = 6 Adverse events
• n = 4 Consent withdrawal 
• n = 3 Physician decision








Figure 1. CONSORT diagram: enrollment, intent-to-treat and safety populations, a
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staining).21 The categories were selected based on the
distribution of the H-score (range from 0 to 300) to divide
the population into low, medium, and high groups. The
following Trop-2 expression categories were used: H-score
0 to <100: Trop-2 low; H-score 100-200: Trop-2 medium;
H-score >200-300: Trop-2 high. The status of germline
BRCA1/2 mutations was collected at baseline, if known.Statistical analyses
Subgroup analyses of PFS, OS, and ORR by biomarker were
carried out. Efficacy analyses were based on data from the
primary study analysis (cutoff date 11 March 2020) of the
brain metastases negative patient population.18 Only pa-
tients with known Trop-2 or BRCA1/2 results are included in
the analysis. The analyses were exploratory in nature, with
no adjustment for multiple testing and no formal testing of
benefit of SG versus TPC subgroups.
PFS was defined as the time from randomization until
objective tumor progression or death or censored at the last
radiographic assessment for patients without progression or
death. PFS and OS were analyzed using the KaplaneMeier
method, with medians and corresponding 95% CIs deter-
mined according to the Brookmeyer and Crowley method
with log-log transformation. CIs for ORR were calculated by
the Clopper-Pearson method.RESULTS
Patients
As reported previously, 529 patients were enrolled in
ASCENT (Figure 1); 61 patients had brain metastases at
baseline and 468 patients had no history of brain metas-
tases. Of the patients who were negative for brain metas-
tases (primary efficacy dataset) and included in this analysis,
235 patients were randomized to receive SG, and 233domized
9
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2), gemcitabine (n ¼ 38), or capecitabine (n ¼ 33).
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Table 1. Demographics assessed in patients who were negative for brain
metastases
SG (n [ 235) TPC (n [ 233)
Median age (range), years 54 (29-82) 53 (27-81)
Female, n (%) 233 (99) 233 (100)
Race or ethnic group, n (%)
White 188 (80) 181 (78)
Black 28 (12) 28 (12)
Asian 9 (4) 9 (4)
Other or not specified 10 (4) 15 (6)
ECOG PS, n (%)
0 108 (46) 98 (42)
1 127 (54) 135 (58)
BRCA1/2 mutational status, n (%) 149 (63) 143 (61)
Positive 16 (7) 18 (8)
Negative 133 (57) 125 (54)
Trop-2 expression, n (%) 151 (64) 139 (60)
(High) H-score >200-300 85/151 (56) 72/139 (52)
(Medium) H-score 100-200 39/151 (26) 35/139 (25)
(Low) H-score 0 to <100a 27/151 (18) 32/139 (23)
Initial diagnosis of TNBC,b n (%)
Yes 165 (70) 157 (67)
No 70 (30) 76 (33)
Median previous anticancer regimens,c
n (range)
4 (2-17) 4 (2-14)
Most common prior chemotherapy, n (%)
Taxaned 235 (100) 233 (100)
Cyclophosphamide 192 (82) 192 (82)
Carboplatin 147 (63) 160 (69)
Capecitabine 147 (63) 159 (68)
Previous PARP inhibitor, n (%) 17 (7) 18 (8)
Previous use of checkpoint inhibitors, n (%) 67 (29) 60 (26)
Most common sites of disease,e n (%)
Lung only 108 (46) 97 (42)
Liver 98 (42) 101 (43)
Bone 48 (20) 55 (24)
BRCA, breast cancer gene; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; H-score, histochemical score; PARP, poly (ADP-ribose) polymerase; SG,
sacituzumab govitecan; TNBC, triple-negative breast cancer; TPC, treatment of
physician’s choice; Trop-2, trophoblast cell-surface antigen 2.
a In this H-score group, seven and four patients in the SG and TPC arms, respectively,
had no Trop-2 expression.
b Patients in study either had TNBC at initial diagnosis or had hormone receptor-
positive disease that converted to hormone-negative at time of study entry.
c Anticancer regimens refer to any treatment regimen that was used to treat breast
cancer in any setting.
d Includes paclitaxel, paclitaxel albumin, and docetaxel.
e Based on independent central review of target and non-target lesions at baseline.
A. Bardia et al. Annals of Oncologypatients were randomized to receive TPC (54% eribulin, 20%
vinorelbine, 13% capecitabine, and 12% gemcitabine).
Patients in the SG- versus TPC-treated cohorts had a median
age of 54 years (range, 29-82 years) and 53 years (range,
27-81 years; Table 1), respectively. The most common prior
chemotherapy received in the SG- versus TPC-treated co-
horts, respectively, was cyclophosphamide (82% each),
carboplatin (63% versus 69%), and capecitabine (63% versus
68%); all patients received a prior taxane. The median
number of prior anticancer regimens was 4 (range, 2-17).
Demographics and baseline characteristics of patients
with known and unknown Trop-2 expression and those of
patients with known or unknown BRCA1/2 mutational sta-
tus are presented in Supplementary Tables S1 and S2,
respectively, available at https://doi.org/10.1016/j.annonc.2
021.06.002. Demographics and baseline characteristics of
patients included in the biomarker analyses were well-
balanced across treatment arms. Patients who were not
included in the biomarker analyses due to unknown Trop-2
expression or BRCA1/2 mutational status generally had
similar characteristics as those who were included.
Compared with patients who were included in the analyses,
minor differences were observed for prior use of checkpoint
inhibitors in patients who were not included in the Trop-2
analysis, and for median age and prior use of checkpoint
inhibitors in patients who were not included in the BRCA1/2
analysis. Trop-2 expression levels in patients who did not
have TNBC at initial breast cancer diagnosis were broadly
similar to those of patients with TNBC at initial breast
cancer diagnosis (data not shown).
Among 235 patients who were treated with SG, 151
(64%) had archival tumors evaluated for Trop-2 expression.
Of these, the majority of patients had a high H-score [n ¼
85 (56%)], with a medium and low H-score found in 26%
(n ¼ 39) and 18% (n ¼ 27) of patients, respectively. In the
SG arm, there were seven patients in the low H-score group
who had no Trop-2 expression. A similar distribution of
Trop-2 expression was observed in patients who received
single-agent chemotherapy with high, medium, and low H-
scores of 52%, 25%, and 23%, respectively. In the TPC arm,
there were four patients in the low H-score group who had
no Trop-2 expression. Data on Trop-2 expression in primary
versus metastatic tumors were not collected.
Germline BRCA1/2 mutational status was known in 149
(63%) patients who received SG and in 143 (61%) of pa-
tients who received TPC. Of those with known germline
BRCA1/2 status, there were 16 of 149 patients (11%) who
were BRCA1/2-positive (germline pathogenic variants in
either BRCA1 or BRCA2) and 133 of 149 patients (89%) who
were BRCA1/2-negative (also considered to be germline
BRCA wild type) in the SG arm, and 18 of 143 (13%)
BRCA1/2-positive and 125 of 143 (87%) BRCA1/2-negative
patients in the TPC arm.Trop-2 expression and efficacy outcomes
SG-treated patients with high, medium, and low Trop-2 H-
scores had median PFS of 6.9 months (95% CI 5.8-7.4Volume 32 - Issue 9 - 2021months), 5.6 months (95% CI 2.9-8.2 months), and 2.7
months (95% CI 1.4-5.8 months), respectively. Compared
with SG, TPC-treated patients had numerically lower median
PFS across high (2.5 months; 95% CI 1.5-2.9 months), me-
dium (2.2 months; 95% CI 1.4-4.3 months), and low (1.6
months; 95% CI 1.4-2.7 months) Trop-2 H-scores
(Figure 2A). Median OS with SG treatment was 14.2 months
(95% CI 11.3-17.5 months), 14.9 months (95% CI 6.9 months
to not evaluable), and 9.3 months (95% CI 7.5-17.8 months)
in patients with high, medium, and low Trop-2 scores,
respectively. In patients with who received TPC, median OS
was 6.9 months (95% CI 5.3-8.9 months), 6.9 months (95%
CI 4.6-10.1 months), and 7.6 months (95% CI 5.0-9.6
months) for high, medium, and low Trop-2 H-scores,
respectively; Figure 2B).
The ORR in SG-treated patients with high, medium, and
low Trop-2 H-scores was 44%, 38%, and 22%, respectively.
In comparison, the ORR in the TPC arm was 1%, 11%, andhttps://doi.org/10.1016/j.annonc.2021.06.002 1151
Trop-2 high H-score: >200-300 Trop-2 medium H-score: 100-200 Trop-2 low H-score: 0 to <100



























Median PFS, months (95% CI) 6.9 (5.8-7.4)
SG (n = 85)
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TPC (n = 35)
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TPC (n = 32)
Number at risk
SG – Trop-2 high 50 18 8 1 0
SG – Trop-2 medium 18 5 2 1 0
SG – Trop-2 low 7 4 2 1 0
TPC – Trop-2 high 5 1 0 0 0
TPC – Trop-2 medium 5 0 0 0 0
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TPC – Trop-2 high 46 19 8 0 0
TPC – Trop-2 medium 20 9 6 3 0
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Figure 2. (A) Progression-free survival by Trop-2 expression. (B) Overall survival by trophoblast cell-surface antigen 2 (Trop-2) expression.
CI, confidence interval; H-score, histochemical score; OS, overall survival; PFS, progression-free survival; SG, sacituzumab govitecan; TPC, treatment of physician’s choice;
Trop-2, trophoblast cell-surface antigen 2.
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respectively (Figure 3).BRCA mutational status and efficacy outcomes
Compared with TPC, treatment with SG resulted in
numerically higher median PFS, median OS, and response
outcomes, regardless of germline BRCA1/2 mutation status1152 https://doi.org/10.1016/j.annonc.2021.06.002at study entry (Table 2). In BRCA1/2-positive patients, the
median PFS was 4.6 versus 2.5 months in SG-treated versus
TPC-treated patients, respectively; median OS was 15.6
versus 4.4 months in SG-treated versus TPC-treated
patients, respectively. In BRCA1/2-negative patients, the
median PFS was 4.9 and 1.6 months in SG-treated versus
TPC-treated patients, respectively; median OS was 10.9




















Trop-2 high H-score: >200-300 (n = 157) Trop-2 medium H-score: 100-200 (n = 74) Trop-2 low H-score: 0 to <100 (n = 59)
ORR, % (n) 44 (37)
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Figure 3. Objective response rate by Trop-2 expression.
CI, confidence interval; H-score, histochemical score; ORR; objective response rate; SG, sacituzumab govitecan; TPC, treatment of physician’s choice; Trop-2, trophoblast
cell-surface antigen 2.
Table 2. ORR, PFS, and OS summary by germline BRCA1/2 status
Germline BRCA1/2-positive Germline BRCA1/2-negative
SG (n ¼ 16) TPC (n ¼ 18) SG (n ¼ 133) TPC (n ¼ 125)
ORR, n (%) 3 (19) 1 (6) 44 (33) 7 (6)
Odds ratio (95% CI) 3.9 (0.4-42.2) 8.3 (3.6-19.4)
Median PFS, months (95% CI) 4.6 (1.3-10.3) 2.5 (0.8-5.5) 4.9 (3.8-5.9) 1.6 (1.5-2.5)
HR (95% CI) 0.6 (0.2-1.6) 0.4 (0.3-0.6)
Median OS, months (95% CI, months) 15.6 (6.2-NE) 4.4 (3.6-9.7) 10.9 (9.6-13.4) 7.0 (5.6-8.2)
HR (95% CI) 0.4 (0.2-0.9) 0.5 (0.4-0.7)
BRCA, breast cancer gene; CI, confidence interval; HR, hazard ratio; NE, not evaluable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SG,
sacituzumab govitecan; TPC, treatment of physician’s choice.
A. Bardia et al. Annals of Oncologyrespectively. In BRCA1/2-positive patients, ORR was 19%
versus 6% in SG-treated versus TPC-treated patients,
respectively. In BRCA1/2-negative patients, the ORR was
33% versus 6% in SG-treated versus TPC-treated patients,
respectively.
DISCUSSION
In the pivotal phase III ASCENT study, SG demonstrated
improved outcomes compared with TPC (eribulin, vinor-
elbine, gemcitabine, or capecitabine), thereby becoming the
first Trop-2-directed antibodyedrug conjugate to show a
significant PFS and OS benefit compared with standard-of-
care chemotherapy in the second-line or greater mTNBC
setting.18 These efficacy data, however, were based on a
patient population unselected for Trop-2 expression. In this
prespecified biomarker analysis, we assessed efficacy out-
comes by tumor membrane Trop-2 expression and BRCA1/2
mutational status. Our results show the SG arm had
numerically higher efficacy outcomes in high and medium
Trop-2 expression subgroups compared with those in the
TPC arm. The benefit of SG over TPC was also similar in
BRCA1/2-positive and -negative patients.
Although Trop-2 is overexpressed across a variety of
epithelial cancers, overexpression is more common in TNBC
compared with other breast cancer subtypes.22 Preclinical
studies of TNBC demonstrated that expression levels ofVolume 32 - Issue 9 - 2021Trop-2 and homologous recombination repair deficiency can
influence the antitumor activity of SG; SG provided higher
activity in preclinical models with higher tumor Trop-2
expression and homologous recombination deficiency.23 In
addition, the presence of intratumoral heterogeneity in
Trop-2 expression in clinical breast cancer samples and the
possibility for Trop-2 plasticity in the tumor microenviron-
ment highlight the need to assess the clinical impact of SG
in TNBC tumors with varying Trop-2 expression.24 The
availability of the ASCENT clinical dataset allowed for
assessment of SG efficacy in patients with varying tumor
Trop-2 expression and the potential for Trop-2 as a
biomarker of response in TNBC.
In this study, outcomes among Trop-2 subgroups were
numerically higher with SG versus TPC treatment in patients
with high and medium Trop-2 expression; SG-treated pa-
tients with high/medium Trop-2 expression had similar
median PFS, median OS, and response rates as SG-treated
patients in the overall primary analysis from ASCENT.18 As
the majority of breast cancers express Trop-2,3,4 the number
of patients with low Trop-2-expression tumors was small.
These results suggest evaluating Trop-2 expression may not
be needed to predict which patients are unlikely to derive
benefit from SG versus TPC, but the small numbers of pa-
tients in the low Trop-2 expression groups and absence of
formal testing limit definitive conclusions on the benefit ofhttps://doi.org/10.1016/j.annonc.2021.06.002 1153
Annals of Oncology A. Bardia et al.SG (or lack thereof) in patients with low Trop-2 expression.
Additional studies are needed to address whether higher
Trop-2 expression is predictive of better response to SG and
if primary tumor Trop-2 expression is predictive of response
to SG in mTNBC. Finally, although high Trop-2 expression
has previously been associated with poor prognosis in
breast cancer,3,5 this study did not suggest an adverse
prognostic effect of high Trop-2 expression in either treat-
ment arm.
Because the BRCA1 and BRCA2 genes encode proteins
involved in double-stranded DNA break repair, it is hy-
pothesized that cancers with pathogenic variants in BRCA1/
2 may be more sensitive to chemotherapies that cause DNA
damage, such as platinum-based regimens.25-27 Due to the
strong association of TNBC with germline BRCA1/2 muta-
tions,13,14,28 we assessed whether TNBC with germline
pathogenic variants in BRCA1/2 had increased sensitivity to
or was a predictive biomarker for response to SG, which
primarily exerts its antitumor activity by eliciting DNA
damage. In our analysis, there did not appear to be a dif-
ference in the effect size of SG between BRCA1/2-positive
and -negative patients. Due to the small numbers of pa-
tients who were BRCA1/2-positive, further comparison of
efficacy outcomes with BRCA1/2-negative patients was not
carried out. However, DNA repair may be altered through
other mechanisms beyond germline mutations, and addi-
tional research is needed into biomarkers of response and
resistance for SG. As we are unable to exclude secondary
reversion mutations and due to the advanced setting of the
ASCENT trial, these data are not sufficient to draw definitive
conclusions on the predictive value of germline BRCA mu-
tations for SG in advanced TNBC.
The primary limitations of this study are that ASCENT was
not powered to detect predictive effects, and there was no
formal testing carried out between treatment arms in this
subanalysis. In addition, the number of patients in both the
low Trop-2 expression subgroup and the germline BRCA1/2-
positive subgroup were small, which limited meaningful
interpretation of the data when compared with other
subgroups. Formal statistical analysis of Trop-2 expression
and various baseline patient characteristics to determine a
potential correlation was not carried out, due to the vari-
ability of patient characteristics and methodological con-
cerns about exploratory non-hypothesis-based post hoc
analyses. These data also reflect the current measurement
of Trop-2 expression by IHC, and future assays may be
developed to better quantify its expression. An additional
limitation is that these data did not assess somatic BRCA1/2
mutations in germline BRCA1/2-negative patients or mu-
tations in other genes associated with homologous
recombination, such as PALB2. Finally, differences in Trop-2
expression in primary breast cancers compared with met-
astatic lesions were not assessed and could be different.
Most samples were archival tumor samples, and the bi-
opsies were not from baseline when patients started ther-
apy, so it is uncertain if the Trop-2 expression was reflective
of the baseline state when the patient went on study,
especially as Trop-2 may be a dynamic biomarker.1154 https://doi.org/10.1016/j.annonc.2021.06.002Conclusion
The collective results from the current study suggest SG
benefits patients with previously treated mTNBC expressing
high/medium Trop-2 compared with standard-of-care sin-
gle-agent chemotherapy and regardless of germline BRCA1/
2 mutation status. Further studies are warranted to fully
elucidate outcomes among these patient populations and
those with low Trop-2 expression. Currently, studies are
ongoing to further evaluate SG in earlier-stage TNBC and
human epidermal growth factor receptor 2 (HER2)-negative
breast cancer (NeoSTAR, NCT04230109; SASCIA,
NCT04595565), in combination with other agents for the
treatment of mTNBC (SEASTAR, NCT03992131; MORPHEUS-
TNBC, NCT03424005; NCT04468061), and for the treatment
of hormone receptor-positive/HER2-negative metastatic
breast cancer (TROPiCS-02, NCT03901339). Biomarker data
from these studies will provide further insight into the
relationship of Trop-2 expression and germline BRCA1/2
mutation status as a potential predictive biomarker of
response to SG in breast cancer.
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